Evolving NSCLC Treatment Paradigm
EP. 1: Pathology of Stage IV Lung Adenocarcinoma
August 23rd 2018
EP. 2: Molecular Testing in Stage IV Lung Cancer
August 23rd 2018
EP. 3: Emerging Predictive Biomarkers in NSCLC
August 23rd 2018
EP. 4: Frontline Therapy for EGFR Plus NSCLC: Osimertinib's Impact
August 23rd 2018
EP. 5: ALK/ROS1-Rearranged NSCLC: Approaching Therapy
August 23rd 2018
EP. 6: Sequencing Therapy in ALK/ROS1-Rearranged NSCLC
August 23rd 2018
EP. 7: Treatment of BRAF-Mutant NSCLC
August 23rd 2018
EP. 8: Benefit of Pembrolizumab in NSCLC: The KEYNOTE Trials
August 23rd 2018
EP. 9: Chemo-Immunotherapy in NSCLC: The KEYNOTE-189 Trial
August 23rd 2018
EP. 10: IMpower150: Combining VEGF and I-O Therapy in NSCLC
August 23rd 2018
EP. 11: Dual Checkpoint Inhibition in NSCLC: CheckMate-227
August 23rd 2018
EP. 12: Considering Use of I-O Therapy in Driver Mutation NSCLC
August 23rd 2018
EP. 13: Trials of I-O Therapy in Driver Mutation NSCLC
August 23rd 2018
EP. 14: Driver Mutation NSCLC: Combining Targeted and I-O Therapy
August 23rd 2018
